Ronald D. Wiehle — Endo Lab

2012

Progesterone Receptor Modulators Induce Apoptosis in Mammary Tumors and Uterine Leiomyomas

·doi:10.1007/978-94-007-4917-7_8

nonrandomized-trial 2011

Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance

The AAPS journal ·doi:10.1208/s12248-011-9304-7

Telapristone is a selective progesterone antagonist that is being developed for the long-term treatment of symptoms associated with endometriosis and uterine fibroids. The population pharmacokinetics of telapristone (CDB-4124) and CDB-4453 …

lab-animal 2010

CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis

Cancer prevention research (Philadelphia, Pa.) ·doi:10.1158/1940-6207.capr-10-0244

CDB-4124 (Proellex or telapristone acetate) is a modulator of progesterone receptor (PR) signaling, which is currently employed in preclinical studies for prevention and treatment of breast cancer and has been used in clinical studies for t…

2010

Progesterone Receptor Modulators in Endometriosis: A New Therapeutic Option

·doi:10.5005/jp/books/11032_27

lab-animal 2010

The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells

Fertility and sterility ·doi:10.1016/j.fertnstert.2009.11.031

OBJECTIVE: To evaluate the effects of selective P receptor (PR) modulator CDB4124 on cell proliferation and apoptosis in cultured human uterine leiomyoma smooth muscle (LSM) cells and control myometrial smooth muscle (MSM) cells in matched …